Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients

We recently showed that the outcome of multiple myeloma (MM) patients treated in the REPEAT study (evaluation of lenalidomide combined with low-dose cyclophosphamide and prednisone (REP) in lenalidomide-refractory MM) was markedly better than what has been described with cyclophosphamide-prednisone...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Oncotarget
Prif Awduron: Franssen, Laurens E., Nijhof, Inger S., Bjorklund, Chad C., Chiu, Hsiling, Doorn, Ruud, van Velzen, Jeroen, Emmelot, Maarten, van Kessel, Berris, Levin, Mark-David, Bos, Gerard M.J., Broijl, Annemiek, Klein, Saskia K., Koene, Harry R., Bloem, Andries C., Beeker, Aart, Faber, Laura M., van der Spek, Ellen, Raymakers, Reinier, Sonneveld, Pieter, Zweegman, Sonja, Lokhorst, Henk M., Thakurta, Anjan, Qian, Xiaozhong, Mutis, Tuna, van de Donk, Niels W.C.J.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Impact Journals LLC 2018
Pynciau:
Research Paper
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6188055/
https://ncbi.nlm.nih.gov/pubmed/30338042
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.26131
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg